SEA-CD70 targets CD70 on myeloid blasts, enhancing immune response and disrupting CD70/CD27 interaction, showing potential in MDS and AML treatment. The phase 1 study reported a 44% objective response ...
Researchers from Ambrx Inc. and Novocodex Biopharmaceuticals Co. Ltd. presented preclinical data for ARX-305, a next-generation anti-CD70 antibody-drug conjugate (ADC), being developed for the ...
ADCs in Preclinical Development for the Treatment of B-cell Malignancies With the evolving clinical data demonstrating the feasibility of the ADC platform in hematologic malignancies, the development ...
Monoclonal antibodies are fundamental to modern biomedical research, therapeutic development, and diagnostic applications. However, hybridoma-derived cell lines, which are the traditional source of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback